Focused On-demand Library for Transmembrane channel-like protein 8

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
Q8IU68

UPID:
TMC8_HUMAN

ALTERNATIVE NAMES:
Epidermodysplasia verruciformis protein 2

ALTERNATIVE UPACC:
Q8IU68; Q2YDC0; Q8IWU7; Q8N358; Q8NF04

BACKGROUND:
The Transmembrane channel-like protein 8, alternatively named Epidermodysplasia verruciformis protein 2, is identified as a probable ion channel. Its function is integral to ion transport mechanisms across cellular membranes, a process critical for cell signaling and equilibrium.

THERAPEUTIC SIGNIFICANCE:
Its association with Epidermodysplasia verruciformis 2, characterized by an abnormal reaction to certain human papillomaviruses and a high risk of skin cancer, underscores the importance of this protein in medical research. Exploring the role of Transmembrane channel-like protein 8 could lead to groundbreaking therapeutic approaches for this rare skin disorder and its oncogenic outcomes.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 95 of 8789